2014
Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial.
Bastholt L, Brose M, Jarzab B, Schlumberger M, Siena S, De La Fouchardiere C, Paschke R, Deshpande H, Shi Y, Elisei R, Gao M, Li L, Prins K, Walker H, Mitchell D, Lettieri J, Molnar I, Kappeler C, Pena C. Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial. Journal Of Clinical Oncology 2014, 32: 6061-6061. DOI: 10.1200/jco.2014.32.15_suppl.6061.Peer-Reviewed Original Research
2013
Vandetanib for aggressive and symptomatic medullary thyroid cancer
Deshpande H, Carling T, Khan N, Holt E. Vandetanib for aggressive and symptomatic medullary thyroid cancer. Journal Of Clinical Practice 2013, 10: 275-282. DOI: 10.2217/cpr.13.17.Peer-Reviewed Original ResearchMedullary thyroid cancerThyroid cancerSymptomatic medullary thyroid cancerMetastatic medullary thyroid cancerNew tyrosine kinase inhibitorsThyroid cancer accountsTyrosine kinase inhibitorsAggressive metastatic formsGrowth factor receptorProto-oncogene RETCancer accountsClinical trialsSignificant symptomsMetastatic formSporadic formsMalignant cellsUS FDAClinical useVandetanibKinase inhibitorsFactor receptorCancerFirst agentPhase IIDisease
2012
Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer
Deshpande H, Sheth K, Sosa J, Roman S. Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer. Clinical Medicine Insights Oncology 2012, 6: cmo.s8305. PMID: 23133319, PMCID: PMC3489097, DOI: 10.4137/cmo.s8305.Peer-Reviewed Original ResearchMedullary thyroid carcinomaProgressive medullary thyroid carcinomaAdvanced medullary thyroid carcinomaManagement of MTCMedullary thyroid cancerAdvanced diseasePharmacotherapy optionsConventional chemotherapyThyroid cancerThyroid carcinomaNovel treatmentsUS FoodDrug AdministrationTreatmentTherapyDiseaseEfficacyTolerabilityChemotherapyPatientsCarcinomaVandetanibCancerAdministration
2011
Medullary thyroid cancer in the past, present and future: from bench to bedside
Deshpande H, Morgensztern D, Sosa J. Medullary thyroid cancer in the past, present and future: from bench to bedside. Expert Review Of Endocrinology & Metabolism 2011, 6: 585-597. DOI: 10.1586/eem.11.44.Peer-Reviewed Original ResearchMedullary thyroid cancerThyroid cancerManagement of MTCMaximum survival benefitSystemic treatment optionsHigh-volume surgeonsMultiple endocrine neoplasiaFirst clinical descriptionRET proto-oncogeneMetastatic diseaseSurvival benefitProphylactic thyroidectomyTreatment optionsSpecialized centersEndocrine neoplasiaClinical descriptionPatientsCancerDiseaseDiagnosisProto-oncogeneImportant advancesThyroidectomyComplicationsSurgery